programas cribado cancer


Nota Bibliográfica

Esta Nota es una recopilación de publicaciones (artículos, informes, libros) sobre cribado de cáncer resultado de una revisión no sistemática de la literatura.

Podéis dirigir vuestros comentarios o sugerencias sobre la Nota a:

Josep A Espinás. Pla Director d'Oncología de Catalunya.
Correo electrónico: Esta dirección electrónica esta protegida contra spam bots. Necesita activar JavaScript para visualizarla

Nota bibliográfica cribado c próstata 2013-03

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, et al. Prostate Cancer Mortality in the Finnish Randomized Screening Trial. Journal of the National Cancer Institute 2013 March 11 DOI:10.1093/jnci/djt038.

Conclusions At 12 years, a relatively conservative screening protocol produced a small, non-statistically significant PC-specific mortality reduction in the Finnish trial, at the cost of moderate overdiagnosis.


Nota bibliográfica cribado c próstata 2013-02

Concato J. Probability, Uncertainty, and Prostate Cancer. (editorial). Annals of Internal Medicine 2013 February 5;158(3):211-212. DOI:10.7326/0003-4819-158-3-201302050-00012.

Gulati R, Gore JL, Etzioni R. Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening StrategiesModel Estimates of Potential Benefits and Harms. Annals of Internal Medicine 2013 February 5;158(3):145-153. DOI:10.7326/0003-4819-158-3-201302050-00003.

Conclusion: Compared with standard screening, PSA screening strategies that use higher thresholds for biopsy referral for older men and that screen men with low PSA levels less frequently can reduce harms while preserving lives.


Nota bibliográfica cribado c próstata 2013-01

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2013 Jan;189(1 Suppl):S2-S11. DOI:10.1016/j.juro.2012.11.014; 10.1016/j.juro.2012.11.014. PMID:23234625.

CONCLUSIONS: Although recently published trials show different results regarding the impact of prostate cancer screening on mortality, both suggest that prostate cancer screening leads to overdetection and overtreatment of some patients. Therefore, men should be informed of the risks and benefits of prostate cancer screening before biopsy and the option of active surveillance in lieu of immediate treatment for certain men diagnosed with prostate cancer.

Howrey BT, Kuo YF, Lin YL, Goodwin JS. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci 2013 Jan;68(1):56-61. DOI:10.1093/gerona/gls135; 10.1093/gerona/gls135. PMID:22562961.

CONCLUSIONS: PSA testing was associated with modest reductions in prostate cancer mortality and large increases in the number of men overdiagnosed with and overtreated for prostate cancer. The results are similar to those obtained by the large European randomized prospective trial of PSA testing.


Nota bibliográfica cribado c próstata 2012-12

Underwood DJ, Zhang J, Denton BT, Shah ND, Inman BA. Simulation optimization of PSA-threshold based prostate cancer screening policies. Health Care Manag Sci 2012 Dec;15(4):293-309.
 DOI:10.1007/s10729-012-9195-x. PMID:22302420.
We describe a simulation optimization method to design PSA screening policies based on expected quality adjusted life years (QALYs). Our method integrates a simulation model in a genetic algorithm which uses a probabilistic method for selection of the best policy. We present computational results about the efficiency of our algorithm. The best policy generated by our algorithm is compared to previously recommended screening policies. Using the policies determined by our model, we present evidence that patients should be screened more aggressively but for a shorter length of time than previously published guidelines recommended.


Nota bibliográfica cribado de próstata 2012-10

Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, et al. Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer? J Clin Oncol 2012 Oct 1.  DOI: 10.1200/JCO.2012.44.0586


Página 4 de 14

web desarrollada y mantenida por :